Reducing the expression and activation of TRPM4 by genetic deletion or the TRPM4 inhibitors, such as 9‐phenantrol, glibenclamide, 4‐Chloro‐2‐(2‐(2‐chlorophenoxy) acetamido) benzoic acid (CBA), and 4‐Chloro‐2‐(2‐(naphthalene‐1‐yloxy) acetamido) benzoic acid (NBA), shows a promising protective effect in MS [72, 74]. This evidence concerns the gene TRPM4 and myeloid sarcoma.